$INCY

Tray Thomas sold $264K of INCY

Tray Thomas (Principal Accounting Officer) sold 2,639 shares of INCYTE CORP (INCY) at $100.00 ($0.26M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tray Thomas
Published Jun 8, 2026, 8:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INCY
Neutral
high confidence
Mentioned
$INCY
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, execution date (June 4), and that it was conducted under a pre-arranged Rule 10b5-1 plan.

02

Market read

This is a routine insider sale disclosure with limited incremental trading signal for INCY.

03

What to watch

The article provides only the sale details (size/price/plan) and no context on total compensation, tax-motivated selling, or whether other insiders are selling/buying concurrently.

Relevance 3/10Novelty 2/10Timing: Filed June 8; sale executed June 4.

Background

The article reports an SEC Form 4 insider transaction for Incyte, filed via EDGAR.

Company-level read

Ticker impact

$INCYNeutralHigh confidence
Context

Incyte Form 4 shows Tray Thomas (principal accounting officer) sold 2,639 shares at $100/share under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any effect is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider sale with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive weight.

Market effects

No sector read-through; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution; traders may still monitor for clustering of sales.

Key entities

  • INCY

    Incyte Corp; subject of the Form 4 insider sale disclosure.

  • Tray Thomas

    Principal Accounting Officer who sold shares.

  • Rule 10b5-1 plan

    Pre-arranged plan indicating the sale was scheduled in advance.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INCYHigh

Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks

Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (INCY) and Biogen (BIIB) as top stock picks, focusing on healthcare over AI. Incyte's stock is up 22% this year, with strong earnings and a growing drug pipeline. The company reported 38% revenue growth and raised its 2026 sales guidance. Risks include Jakafi's patent expiration and competition for Opzelura.

$INCYHighAI 9/10

Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?

Incyte (INCY) and Revolution Medicines (RVMD) are competing in the KRAS inhibitor market. RBC noted INCY's upcoming ESMO data for its KRAS G12D inhibitor, while Bernstein raised RVMD's price target. RVMD received FDA approval for Rasonque. INCY reported Q2 2026 revenue of $1.67B, while RVMD had no product revenue but $3.9B in cash. Institutional investors favor RVMD, with notable holdings by Farallon Capital and Baker Bros. Advisors.

$INCYHighAI 8/10

How Q2 Beat, Opzelura Demand and Niktimvo Approval At Incyte (INCY) Has Changed Its Investment Story

Incyte (INCY) reported Q2 2026 earnings and revenue above expectations, driven by strong demand for Jakafi and Opzelura. The company raised its 2026 net product revenue guidance and received FDA approval for Niktimvo, adding a new therapy to its portfolio. Analysts project varying revenue and earnings estimates for 2029, with the company targeting $5.8 billion in revenue and $1.1 billion in earnings, while the lowest estimates predict $5.4 billion in revenue and $1.2 billion in earnings.

$INCYHighAI 8/10

Incyte Stock: Is Wall Street Bullish or Bearish?

Incyte (INCY) raised its 2026 revenue forecast to $5.13B-$5.26B after a CMS settlement. Q2 2026 net sales rose 40% to $1.49B, and adjusted EPS was $3.09, beating estimates. Analysts expect FY 2026 EPS to decrease 52.7% YoY to $2.64. The stock has a 'Moderate Buy' consensus rating, with a mean price target of $127.09.